跳至主要内容
临床试验/NCT01820884
NCT01820884进行中(未招募)不适用

The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma: A Multicenter, Prospective, Randomized Trial

Ding Ma3 个研究点 分布在 1 个国家目标入组 240 人开始时间: 2012年11月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
240
试验地点
3
主要终点
Disease-free survival (DFS)

研究概览

简要总结

This randomized trial is studying the efficacy and safety of the hysterectomy alone compared with hysterectomy and bilateral salpingo-oophorectomy (BSO) for patients with Stage IA endometrial carcinoma.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Female
接受健康志愿者
否

入选标准

  • •FIGO stage: ⅠA, endometrial carcinoma;
  • •Female, Chinese women;
  • •premenopausal women;
  • •≤ 50 years old;
  • •Pathological diagnosis by curettage/hysteroscopy : G1
  • •No prior treatment;
  • •Provide written informed consent.

排除标准

  • •The suspicious metastasis of ovarian;
  • •Family history of ovarian cancer;
  • •Suffering from other malignancies;
  • •Concurrently participating in other clinical trials;
  • •Unable or unwilling to sign informed consents;
  • •Unable or unwilling to abide by protocol.

研究组 & 干预措施

Total Hysterectomy (TH)

Experimental

Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).

干预措施: TH (Procedure)

Total Hysterectomy (TH)

Experimental

Patients may receive total hysterectomy (TH) and bilateral pelvic and para-aortic lymph node dissection (BPLND).

干预措施: BPLND (Procedure)

TH and bilateral salpingo-oophorectomy (TH/BSO)

Active Comparator

Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.

干预措施: TH/BSO (Procedure)

TH and bilateral salpingo-oophorectomy (TH/BSO)

Active Comparator

Patients may receive total hysterectomy, bilateral salpingo-oophorectomy (BSO) and bilateral pelvic and para-aortic lymph node dissection.

干预措施: BPLND (Procedure)

结局指标

主要结局

Disease-free survival (DFS)

时间窗: 3-year DFS

次要结局

  • Quality of Life(3-year period)
  • Clinical gynecologic endocrine function(1-year period)
  • Overall Survival (OS)(3-year OS)

研究者

发起方
Ding Ma
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ding Ma

Director of the department of Obstetrics and Gynecology, Tongji Hospital

Huazhong University of Science and Technology

研究点 (3)

Loading locations...

相似试验

The Safety of Ovarian Preservation in Stage IA... | 临床试验